WONTECH Obtains Certification for 'Pastel Pro' Medical Device in Taiwan
Approval Granted for Non-Invasive Soft Tissue Procedures and Treatments for Pigment and Vascular Lesions
Full-Scale Push into the Taiwanese Market Begins
[Edaily Reporter Hyera Lee ] WONTECH(336570)announced on the 22nd that it has obtained medical device certification from Taiwan’s health authorities (TFDA) for its laser medical device, “Pastelle Pro.” Image of the Pastelle Pro product. (Photo courtesy of WONTECH) Pastelle Pro has been approved for indications including non-invasive soft tissue procedures, as well as the treatment of pigmented and vascular lesions, tattoo removal, and hair removal. It supports two wavelengths—532 nm and 1064 nm—and, according to WONTECH, can be used in a variety of clinical settings thanks to its specially designed handpiece, which allows for precise adjustment of the irradiation diameter, depth, and energy density. With this certification, WONTECH plans to expand its product portfolio in Taiwan and strengthen its penetration of the local market. Previously, at the global brand event “Wave Taiwan” held in Taiwan last May, the company showcased products such as the Olizio X, Titan, PicoCare Majesty, and Pico Alex, and conducted academic lectures and product exhibitions for local medical professionals. A WONTECH representative stated, “We will establish a stable foundation for growth in the Taiwanese market by expanding academic exchanges and strengthening our product portfolio.”
"Competitors in Greater China are running aggressive promotions for products like RGB Mini and Mini LED. Competition in the high-end segment is intensifying. We are actively leveraging our technologic…
IL SCIENCE CO.,LTD.(307180)announced on the 22nd that it is rapidly expanding its humanoid robot business by broadening the supply of its humanoid robot “ILBOT” to various industries, while also accel…
Rznomics Inc. Logo (Photo: Rznomics Inc.)
#Rznomics Inc. announced on the 22nd that it has received additional research funding from Eli Lilly for joint research on a treatment for hereditary hear…